Australian Patient Groups Follow ACLU/PUBPAT Path in Challenging Gene Patenting
June 16, 2010
Australian Patient Groups Follow ACLU/PUBPAT Path in Challenging Gene Patenting
Cancer Voices Australia, the law firm Maurice Blackburn, and breast cancer patient Yvonne D'Arcy this week took legal action in Australia's Federal Court against four biotech companies — Myriad Genetics, Genetic Technologies, Centre de Recherce de Chul in Canada, and the Cancer Institute in Japan — to challenge the legality of gene patents.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Plaintiffs Challenging Myriad's Aussie BRCA Patent Will Appeal Federal Court's Dismissal of Case
February 20, 2013 / Pharmacogenomics Reporter - ACLU, PUBPAT Seek to Challenge Patentability of Isolated Genes Before Supreme Court
October 12, 2011 / Pharmacogenomics Reporter - Myriad, ACLU Case Hits Higher Court
April 5, 2011 / GenomeWeb Daily News - Narrow Ruling in Bilski Is a Win for Dx Developers, Despite Ambiguity on Gene-Patent Questions
June 30, 2010 / Pharmacogenomics Reporter - UK's NICE Seeks Comments on Updated Guidelines for Familial Breast Cancer Genetic Testing, Treatment
January 23, 2013 / Pharmacogenomics Reporter